Develops biologic therapies for autoimmune diseases and inflammatory disorders.
Theriva Biologics Inc., operating at the forefront of clinical-stage development, focuses on advancing therapeutic solutions for diseases characterized by significant unmet medical needs. The company's diverse pipeline features innovative candidates such as SYN-004, designed to protect the gastrointestinal tract by degrading common intravenous beta-lactam antibiotics. This approach aims to prevent microbiome damage, clostridium difficile infection (CDI), antimicrobial resistance (AMR), and acute graft-versus-host disease (aGVHD) in transplant recipients. Additionally, SYN-020, a recombinant oral formulation of intestinal alkaline phosphatase, targets both local gastrointestinal and systemic diseases.
Founded as Synthetic Biologics, Inc. and rebranded in October 2022, Theriva Biologics is headquartered in Rockville, Maryland. The company is committed to advancing clinical stage products like VCN-01, developed for treating pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. Collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center underscore Theriva Biologics' collaborative approach to innovation and research.
Theriva Biologics also focuses on pioneering solutions like SYN-006 to prevent aGVHD and infections from carbapenem-resistant enterococci, SYN-007 for antibiotic-associated diarrhea with oral ß-lactam antibiotics, SYN-005 for pertussis prevention and treatment, and VCN-11 for cancer treatment. With ongoing clinical trials and strategic partnerships, Theriva Biologics continues to push the boundaries of biopharmaceutical development, aiming to address critical medical challenges and improve patient outcomes globally.